Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
SCPS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: September 04, 2023
Report Source: 2023 2nd Quarter Report
Scopus Biopharma Inc. Stock Analysis SCPS
United States Health Care Nano Cap Report: Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-16. The firm is developing therapeutics targeting serious diseases with significant unmet medical needs. Its lead development programs are CO-sTiRNA and MRI-1867. Its CO-sTiRNA is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. CO-sTiRNA is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA also stimulates TLR9 receptors to activate the body’s immune defense to recognize and kill cancer cells. The company is also developing MRI-1867 for the treatment of SSc. SSc is a chronic, systemic autoimmune disease. MRI-1867, is a peripherally-restricted, dual-action cannabinoid-1, or CB1, receptor inverse agonist and inhibitor of inducible nitric oxide synthase, or iNOS.
Read More Scopus Biopharma Inc (SCPS) Chart
Key Statistics of Scopus Biopharma Inc (SCPS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
728.00P/E Ratio (TTM)
-52 Week Range
Market Cap
16.83KAvg. Volume
3333.07Dividend Yield
-Financial Metrics & Statements of Scopus Biopharma Inc (SCPS)
FAQ's for Scopus Biopharma Inc (SCPS)
- According to Musaffa’s Shariah screening methodology, Scopus Biopharma Inc (SCPS) is currently classified as NOT HALAL as of September 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Scopus Biopharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Scopus Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Scopus Biopharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Scopus Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Scopus Biopharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.